Similarly, Ulixertinib (BVD-523) in an ATP-competitive inhibitor against ERK1/2 that has successfully completed phase I/II trials examining dosage and safety, displaying favourable pharmacokinetics in NRAS-mutant and BRAFV600E advanced solid malignancies, as well as those carrying BRAF mutations at non-V600 sites (NCT01781429) (Sullivan et al., 2018; Wu J. et al., 2021). The gene discussed is BRAF; the disease is cancer.